Small-cell lung cancer: State of the art

Clinical Lung Cancer

Volumn 4, Issue 2, 2002, Pages 87-94

  Hanna, Nasser H ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Carboplatin; Chemoradiation; Cisplatin; Etoposide; Irinotecan; Prophylactic cranial irradiation; Topotecan

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GASTRIN RELEASING PEPTIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERBIMYCIN A; IFOSFAMIDE; IMATINIB; IRINOTECAN; LOMUSTINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; STEM CELL FACTOR RECEPTOR; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; LONG TERM CARE; LUNG SMALL CELL CANCER; LUNG SURGERY; MAINTENANCE THERAPY; META ANALYSIS; NEUTROPENIA; RADIATION DOSE; REVIEW; STANDARD; STATISTICAL ANALYSIS;

EID: 0036749809     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.018     Document Type: Review

References (93)

1. Greenlee RT, Hill-Harmon M, Murray T, et al. Cancer Statistics 2001. CA Cancer J Clin 2001; 51:16.
2. Page N, Read W, Tierney R, et al. The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 2002; 21:305a (Abstract #1216).
3. Johnson B, Grayson J, Makuch R, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 1990; 8:396-401.
4. Johnson D, Einhorn L, Mandelbaum I, et al. Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest 1987; 92:241-246.
5. Lassen U and Hansen H. Surgery in limited stage small cell lung cancer. Ca Treat Rev 1999; 25:67-72.
6. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; 106:32OS-323S.
7. Osterlind K, Hansen H, Hansen H, et al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer 1986; 54:7-17.
8. Johnson D, Bass D, Einhorn L, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the southeastern cancer study group. J Clin Oncol 1993; 11:1223-1229.
9. Perry M, Eaton W, Propert K, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung? N Engl J Med 1987; 316:912-918.
10. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J clin Oncol 1992; 10:890-895.
11. Pignon J, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-1624.
12. Einhorn L, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988; 6:45 1-456.
13. Turrisi A, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271.
14. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 2002; 20:3054-3060.
15. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 1997; 15:2840-2849.
16. Work E, Nielsen O, Bentzen S, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997; 15:3030-3037.
17. Samantas E, Fountzilas G, Briassoulis E, et al. Randomized comparison of early vs late twice-daily chest irradiation concurrently with chemotherapy in limited disease small cell lung cancer. Final results. Proc Am Soc Clin Oncol 2000; 19:491a (Abstract #1919).
18. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893-900.
19. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic irradiation in the combined modality-treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336-344.
20. Murray N, Coldman A. The relationship between thoracic irradiation timing and long-term survival in combined modality therapy of limited small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 1995; 14:360 (Abstract #1099).
21. Bonner J, Sloan J, Shanahan T, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 109; 17:2681-2691.
22. Ettinger D, Seiferheld W, Abrams R, et al. Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (Pts) with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 96-09. Proc Am Soc Clin Oncol 2000; 19:490a (Abstract #1917).
23. Byrne MJ, van Hazel G, Trotter J, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomized controlled trial. Br J Cancer 1989; 60:413-418.
24. Elias A, Ibrahim J, Skarin A, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17:1175-1184.
25. Seifart U, Schroder M, Hans K, et al. Tandem high dose chemotherapy (THD) in patients (Pts) with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2000; 19:547a (Abstract #2159).
26. Goodman G, Crowley J, Livingston R, et al. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. J Clin Oncol 1991; 9:453-457.
27. Arriagada R, Le Chevalier T, Pignon J, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329:1848-1852.
28. Pedersen AG. Diagnosis of CNS-Metastases from SCLC, in Lung Cancer. Basic and Clinical Aspects. Boston, MA: Martinus Nijhoff; 1986:153-182.
29. Einhorn L, Bond W, Hornback, N, et al. Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol 1978; 5:309-313.
30. Shaw E, Su J, Eagan R, et al. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol 1994; 12:2327-2332,
31. Einhorn L. The case against prophylactic cranial irradiation in limited small cell lung cancer. Semin Rad Oncol 1995; 5:57-60.
32. Firsch F, Paulson O, Hansen H, et al. Intracranial metastases in small cell carcinoma of the lung. Correlation of clinical and autopsy findings. Cancer 1982; 50:2433-2437.
33. Kristensen C. Kristjansen P, and Hansen H. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992; 10:1498-1502.
34. Jackson D, Richards F, Cooper M, et al. Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. JAMA 1977; 237:2730-2733.
35. Gregor A, Cull A, Stephens R, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997; 33:1752-1758.
36. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183-190.
37. Fleck J, Einhorn L, Lauer R, et al. Is prophylactic cranial irradiation indicated in small-cell lung cancer? J Clin Oncol 1990; 8:209-214.
38. Auperin A, Arriagada R, Pignon P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476-484.
39. Chute J, Chen T, Feigal, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794-1801.
40. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non cross-resistant chemotherapy. Canc Treat Rep 1982; 66: 439-449.
41. Ihde D, Mulshine J, Kramer B, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022-2034.
42. Johnson D, Einhorn L, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5:1731-1738.
43. Johnson, D, Wolff S, Hainsworth J, et al. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985; 3:170-175.
44. Pujol J, Douillard J, Riviere A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15:2082-2089.
45. Figueredo A, Hyrniuk W, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3:54-64.
46. Eberhardt W, Niederle N, Heidersdorf H, et al. A randomized trial of standard doses carboplatin, etoposide and vincristine (CEV) versus higher doses CEV chemotherapy (CTx) plus GMCSF in extensive disease (ED) small cell lung cancer (SCLC. Proc Am Soc Clin Oncol 1996; 15:383 (Abstract #1147).
47. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5:1864-1873.
48. Furuse K, Kubota K, Nishiwaki Y, et al. Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC). J Clin Oncol 1998; 16:2126-2132.
49. Murray N, Livingston R, Shephard F, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17:2300-2308.
50. Sculier J, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11: 1858-1865.
51. Evans W, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Int Med 1987; 107:451-458.
52. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855-861,
53. Roth B, Johnson D, Einhorn L, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291.
54. Ettinger D, Finkelstein D, Abeloff M, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8:230-240.
55. Hanna N, Sandler A, Loehrer P, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002; 13:95-102.
56. Maurer L, Tulloh M, Weiss R, et al. Comparison of combination chemotherapy-radiation therapy versus cyclophophamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 1980; 45:30-39.
57. Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchi: a randomized, controlled trial. Cancer Chemother Pharmacol 1986; 17:157-160.
58. Johnson D, Bass D, Einhorn L, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993; 11: 1223-1229.
59. Lebeau B, Chastang CL, Allard P, et al. Six vs. twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J 1992; 5:286-290.
60. Giaccone G, Dalesio O, McVie G, et al. Maintenance chemotherapy in small-cell lung cancer: long term results of a randomized trial. J Clin Oncol 1993; 11: 1230-1240.
61. Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol 1996; 14:2337-2344.
62. Bleehen NM, Payers PM, Girling DJ, et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59:584-590.
63. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer 1989; 59:578-583.
64. Bleehan NM, Girling DJ, Machin D, et al. A randomized trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC): survival and prognostic factors. Br J Cancer 1993; 68:1150-1156.
65. Beith JM, Clarke SJ, Woods RL, et al. Long term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 1996; 32A:438-443.
66. Schiller J, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:2114-2122.
67. Sculier JP, Berghman T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998; 19:141-151.
68. Loehrer P, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group Study. J Clin Oncol 1995; 13:2594-2599.
69. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small cell lung cancer. Ann Oncol 2001; 12:463-470.
70. Pujol J, Dames J, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93:300-308.
71. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
72. von Pawel J, Schiller J, Shepherd F, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
73. von Pawel J, Gatzemeier U, Pujol J, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
74. Slevin M, Clark P, Joel S, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7:1333-1340.
75. Einhorn L, Pennington K, and Mclean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990; 17:32-35.
76. Johnson D, Greco A, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990; 8:1613-1617.
77. Bunn P, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13:1632-1641.
78. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or non-compliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998; 16:3323-3328.
79. Richardson G,Tucker M, Venzon D, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-390.
80. Souhami R, Spiro S, Rudd R, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89:577-580.
81. Girling D. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial: Medical Research Council Lung Cancer Working Party. Lancet 1996; 348:563-566.
82. Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group trial. Am J Clin Oncol 2000; 23:68-70.
83. Grant S, Kris M, Houghton A, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus calmette-guerin. Clin Cancer Res 1999; 5:1319-1323.
84. Zangemeister-Wittke U, Stabel R. Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci 1999; 55:1585-1598.
85. Shepherd F, Giaccone G, Dubruyne C, et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCI-CTG and EORTC study. Proc Am Soc Clin Oncol 2001; 20:4a (Abstract #11).
86. Viallet J, Minna JD. Gastrin-releasing peptide (GRP, mammalian bombesin) in the pathogenesis of lung cancer. Prog Growth, Factor Res 1989; 1:89-97.
87. Cuttitta F. Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316:823-826.
88. Chaudhry A, Carrasquillo JA, Avis IL, et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 1999; 5:3385-3393.
89. Nakanishi Y, Mulshine J, Kasprzyk PG, et al. Insulin-like growth factor-I-can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988; 82:354-359.
90. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991; 6:2291-2296.
91. Sekido Y, Takahashi T, Veda R, et al. Recombinant human stem cell factor mediates chemotaxis of small cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993; 53:1709-1714.
92. Krystal G, Hines S, Organ C. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56:370-376.
93. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90:4947-4952.